NCT00656630View on ClinicalTrials.gov

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Alcoholism
Interventions
DRUG

Acamprosate

Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration

DRUG

Naltrexone

50mg capsule, Once daily, 1 week duration

DRUG

Placebo

Matched placebo capsule, 1 week duration

Trial Locations (1)

92037

The Scripps Research Institute, La Jolla

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

The Scripps Research Institute

OTHER

NCT00656630 - Medication Development in Alcoholism: Acamprosate Versus Naltrexone | Biotech Hunter | Biotech Hunter